Author/Authors :
Nastałek, Paweł Pulmonology Clinic - Jagiellonian University Medical College, Krakow, Poland , Kurek, Adam Department of General Surgery - Vascular and Transplant Surgery - Medical University of Silesia, Katowice, Poland , Almgren-Rachtan, Agnieszka Department of Pharmacovigilance - Europharma, Katowice, Poland , Mastalerz-Migas, Agnieszka Department of Family Medicine - Wroclaw Medical University, Poland , Doniec, Zbigniew Department of Pneumonology - Institute of Tuberculosis and Lung Diseases - Rabka Branch, Rabka-Zdroj, Poland
Abstract :
Introduction
Chronic obstructive pulmonary disease (COPD) and asthma are the most common chronic respiratory diseases worldwide. At the moment, there is no information about the preferences of Polish specialists as regards the treatment of asthma and COPD or factors influencing the choice of particular treatment regimens.
Aim
To determine the treatment options most commonly used by experienced pulmonologists and allergists for asthma and COPD and to identify the factors affecting the choice of a particular therapy.
Material and methods
The survey included 224 doctors (pulmonologists and allergists) across Poland and concerned patients diagnosed with asthma (n = 4358) and COPD (n = 3062).
Results
In the case of asthma, the most common therapy applied was inhaled glucocorticosteroids and long-acting β2 agonists. According to 27.2% of doctors, combination therapy was used in 70–80% of patients while 23.7% declared that the proportion of patients receiving such a treatment exceeded 80%. In the case of COPD, anticholinergics were most frequently prescribed when inhaled glucocorticosteroids and long-acting β2 agonists had proved insufficient. According to 21% of specialists, the percentage of patients treated so was 41–50%, while 19% declared the use of this treatment in 71–80% of patients.
Conclusions
The most common treatments for asthma and COPD in Poland are inhaled glucocorticosteroids and long-acting β2 agonists. The main factors influencing treatment decisions are the current GINA and GOLD recommendations as well as patients’ age, comorbidities, and price of treatment.
Keywords :
asthma , chronic obstructive pulmonary disease , therapeutic preferences , therapeutic regimens